Display Settings:

Format

Send to:

Choose Destination

    Biol Psychiatry. 1990 Aug 15;28(4):339-48.

    Up-regulatory effect of estrogen on platelet 3H-imipramine binding sites in surgically menopausal women.

    Sherwin BB, Suranyi-Cadotte BE.

    Department of Psychology, McGill University, Montreal, Canada.

    Although depressive symptoms occur in a considerable number of women following a decrease in circulating estrogen levels, a biological correlate of these mood changes has not been identified. In a prospective, double-blind, cross-over investigation of surgically menopausal women, an increase in the number of tritiated imipramine binding sites on platelets and an improvement of mood occurred with estrogen treatment and were reversed when placebo was administered. In vitro studies indicated that this effect was not due to a direct interaction of the steroid with the imipramine binding site at the same concentrations of estradiol induced in the in vivo study. Together with other evidence, these findings suggest that pharmacological but not physiological doses of estrogen can enhance the density of tritiated imipramine binding sites on platelets in women.

    PMID: 2168762 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Estrogen (Cenestin®, Enjuvia®, Estrace®, ...)

      Estrogen is used to treat hot flushes ('hot flashes'; sudden strong feelings of heat and sweating) in women who are experiencing menopause ('change of life', the end of monthly menstrual periods). Some brands of estrogen...

    • Imipramine (Tofranil®, Tofranil® PM)

      Imipramine tablets and capsules are used to treat depression. Imipramine tablets are also used to prevent bedwetting in children. Imipramine is in a class of medications called tricyclic antidepressants. It treats depres...